Eli Lilly Scores Phase III Migraine Success with Galcanezumab

On May 12, 2017, Eli Lilly announced the successful Phase III results for its calcitonin gene-related peptide (CGRP) monoclonal antibody, galcanezumab, for the prophylactic treatment of episodic and chronic migraine. Galcanezumab is the second CGRP m …

Source: Pharmaceutical Technology - May 15, 2017 Category: Pharmaceuticals Source Type: news